Therapy-related myeloid leukemia.
One of the most serious possible consequences of cancer therapy is the development of a second cancer, especially leukemia. Several distinct subsets of therapy-related leukemia can be distinguished currently. These include classic therapy-related myeloid leukemia, leukemia that follows treatment with agents that inhibit topoisomerase II, acute lymphoblastic leukemia, and leukemias with 21q22 rearrangements or inv(16) or t(15;17). These types of leukemia are discussed in detail in this article.
Thirman
M J
MJ
Section of Hematology/Oncology, Pritzker School of Medicine, University of Chicago, Illinois, USA.
Larson
R A
RA
D000208:Acute Disease; D000970:Antineoplastic Agents / Q000009:adverse effects; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D006801:Humans; D007951:Leukemia, Myeloid / Q000209:etiology* / Q000235:genetics; D009190:Myelodysplastic Syndromes / Q000209:etiology* / Q000235:genetics; D016609:Neoplasms, Second Primary / Q000209:etiology* / Q000235:genetics; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000209:etiology / Q000235:genetics; D011878:Radiotherapy / Q000009:adverse effects
D000970:Antineoplastic Agents